Split therapy: planned neck dissection followed by definitive radiotherapy for a T1, T2 pharyngolaryngeal primary cancer with operable N2, N3 nodal metastases--a prospective study

J Surg Oncol. 2006 Jan 1;93(1):56-61. doi: 10.1002/jso.20399.

Abstract

Background: The management of patients with a small pharyngolaryngeal cancer (T1 and T2) with large nodal metastases is a subject of debate. We present data on the feasibility and outcome of treating these patients with surgery for the nodal metastases followed by definitive radiotherapy.

Methods: Prospective study of 59 patients of small pharyngolaryngeal primary squamous carcinomas with operable (N2/N3) nodal metastasis treated with neck dissection followed by radiotherapy.

Results: Complete nodal clearance was achieved in 54 (90%). The mean nodal size was 4 cm and extranodal extension was seen in 88% of patients in the study group. There were no significant postoperative complications. Median interval between surgery and radiotherapy was 23 days. Forty-nine patients (83%) started their RT within 6 weeks of surgery. With a median follow-up of 25 months, the disease free and overall survival was 54% and 60% (5 years).

Conclusion: The management of patients with a radiocurable pharyngolaryngeal primary with large nodes by this approach is a feasible option with adequate control and survival.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Squamous Cell / radiotherapy*
  • Carcinoma, Squamous Cell / secondary
  • Carcinoma, Squamous Cell / surgery
  • Combined Modality Therapy
  • Disease-Free Survival
  • Feasibility Studies
  • Female
  • Humans
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / radiotherapy*
  • Laryngeal Neoplasms / surgery
  • Lymph Nodes / pathology*
  • Lymphatic Irradiation*
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neck
  • Neck Dissection*
  • Neoplasm Staging
  • Pharyngeal Neoplasms / pathology
  • Pharyngeal Neoplasms / radiotherapy*
  • Pharyngeal Neoplasms / surgery
  • Prospective Studies
  • Treatment Outcome